These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 17514626)

  • 21. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines.
    Mann D; Reynolds K; Smith D; Muntner P
    Ann Pharmacother; 2008 Sep; 42(9):1208-15. PubMed ID: 18648016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis.
    Chhatriwalla AK; Nicholls SJ; Wang TH; Wolski K; Sipahi I; Crowe T; Schoenhagen P; Kapadia S; Tuzcu EM; Nissen SE
    J Am Coll Cardiol; 2009 Mar; 53(13):1110-5. PubMed ID: 19324254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. National improvements in low-density lipoprotein cholesterol management of individuals at high coronary risk: National Health and Nutrition Examination Survey, 1999 to 2002.
    Cullen MW; Stein JH; Gangnon R; McBride PE; Keevil JG
    Am Heart J; 2008 Aug; 156(2):284-91. PubMed ID: 18657658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease.
    Arabul M; Gullulu M; Yilmaz Y; Akdag I; Kahvecioglu S; Eren MA; Dilek K
    Clin Biochem; 2008 Sep; 41(13):1055-8. PubMed ID: 18571502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levels of asymmetric dimethylarginine, nitric oxide and lipid peroxidation markers in patients with end-stage renal disease having peritoneal dialysis treatment.
    Göçmen AY; Sahin E; Koçak H; Tuncer M; Gümüşlü S
    Clin Biochem; 2008 Jul; 41(10-11):836-40. PubMed ID: 18457672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial.
    Grover SA; Lowensteyn I; Joseph L; Kaouache M; Marchand S; Coupal L; Boudreau G;
    Arch Intern Med; 2007 Nov; 167(21):2296-303. PubMed ID: 18039987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines.
    Sachdeva A; Cannon CP; Deedwania PC; Labresh KA; Smith SC; Dai D; Hernandez A; Fonarow GC
    Am Heart J; 2009 Jan; 157(1):111-117.e2. PubMed ID: 19081406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment.
    Morimoto S; Yano Y; Maki K; Sawada K; Iwasaka T
    Am J Nephrol; 2007; 27(6):643-8. PubMed ID: 17878713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry.
    Gitt AK; Juenger C; Jannowitz C; Karmann B; Senges J; Bestehorn K
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):438-44. PubMed ID: 19369876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A guideline-driven assessment of need for cardiovascular disease risk intervention in persons with chronic paraplegia.
    Nash MS; Mendez AJ
    Arch Phys Med Rehabil; 2007 Jun; 88(6):751-7. PubMed ID: 17532897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atherogenic lipoprotein subprofiling.
    Ellington AA; Kullo IJ
    Adv Clin Chem; 2008; 46():295-317. PubMed ID: 19004193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of uncontrolled hyperlipidaemia in high-risk ambulatory patients in primary care.
    Hildemann S; Karmann B; Pittrow D; Barho C; Darius H; Bode C
    Curr Med Res Opin; 2008 Jun; 24(6):1659-68. PubMed ID: 18457604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adult treatment panel III and the management of dyslipidemia risk factors.
    Stein EA
    Postgrad Med; 2002 Oct; 112(4 Suppl):12-7. PubMed ID: 19667595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
    Erdine S; Ro YM; Tse HF; Howes LG; Aguilar-Salinas CA; Chaves H; Guindy R; Chopra P; Moller RA; Schou IM;
    J Hum Hypertens; 2009 Mar; 23(3):196-210. PubMed ID: 18800143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Lipid control in diabetic patients in Extremadura (Spain)].
    Roberto Robles N; Barroso S; Marcos G; Sánchez Muñoz-Torrero JF;
    Endocrinol Nutr; 2009 Mar; 56(3):112-7. PubMed ID: 19627723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of a dietary portfolio diet of cholesterol-lowering foods and a statin on LDL particle size phenotype in hypercholesterolaemic participants.
    Gigleux I; Jenkins DJ; Kendall CW; Marchie A; Faulkner DA; Wong JM; de Souza R; Emam A; Parker TL; Trautwein EA; Lapsley KG; Connelly PW; Lamarche B
    Br J Nutr; 2007 Dec; 98(6):1229-36. PubMed ID: 17663803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of lipid dysfunction in patients on maintenance haemodialysis.
    Altaf A; Halim A; Khan DA; Khalid M; Fatima-Tuz-Zuhra ; Saif I
    J Ayub Med Coll Abbottabad; 2007; 19(4):32-6. PubMed ID: 18693593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.